Regardless of the improvement in clinical outcomes derived with the introduction of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) in the treating patients with advanced non-small cell lung cancer (NSCLC) whose tumours harbour EGFR-activating mutations, prognosis continues to be unfavourable due to the occurrence of possibly intrinsic or acquired resistance. clones; hence, studies… Continue reading Regardless of the improvement in clinical outcomes derived with the introduction